Inspired by these findings, and considering the significant role of bioinformatics in cancer research [22–24], our study leverages biological information to identify CCR7 as a potential key gene in the action of lenalidomide in DLBCL. This evidence concerns the gene CCR7 and diffuse large B-cell lymphoma.